State Bank of India will join a syndicate of global lenders to fund Sun Pharmaceutical Industries Ltd.'s major overseas acquisition, committing approximately $1 billion to the transaction. The deal, valued at $12 billion, ranks among the largest overseas purchases attempted by an Indian pharmaceutical company.

This financing commitment signals State Bank of India's strategic push to support Indian corporations expanding internationally. As India's largest bank by assets, SBI's participation represents institutional validation of the acquisition's business case and potential returns.

The move comes amid intensified global expansion by Indian pharma companies seeking scale and diversification. Sun Pharma has been actively pursuing overseas assets to strengthen its position in regulated markets and reduce dependence on domestic sales.

International syndicated lending for Indian acquirers remains relatively uncommon, making SBI's involvement notable. The bank's participation could encourage other domestic lenders to consider similar overseas financing opportunities, potentially reshaping how Indian companies fund international growth.